# SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

> **NCT05138575** · PHASE2 · RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 53 (estimated)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** Empagliflozin + Potassium Chloride
- **DRUG:** Empagliflozin + Potassium Nitrate
- **DRUG:** Potassium Chloride + Placebo for Empagliflozin

## Key facts

- **NCT ID:** NCT05138575
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-24
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05138575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05138575, "SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05138575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*